Ultragenyx Pharmaceutical Inc. disclosed that its investigational AAV9 gene‑therapy candidate UX111 has produced sustained, significant reductions in cerebrospinal fluid heparan sulfate (CSF‑HS) and meaningful functional improvements in children with Sanfilippo syndrome type A (MPS IIIA) over a follow‑up period of up to 8.5 years, with a median observation of 4.8 years. The data, presented at the World Symposium 2026, were cut off in September 2025 and represent the longest‑term efficacy assessment to date for a gene‑therapy approach to this rare disease.
The median reduction in CSF‑HS was 63.98 %, a figure that exceeds the 50 % threshold often cited as clinically meaningful. In addition, Bayley‑III cognitive raw scores improved by 23.2 points in the early‑stage cohort (n = 17), while receptive, expressive, fine‑motor and gross‑motor scores rose by 8.1, 11.1, 9.0 and 3.9 points, respectively. Eight children reached a 36‑month cognitive developmental age—an outcome not seen in natural‑history patients—while the later‑stage cohort (n = 10) largely maintained communication, independent walking and oral feeding beyond the ages at which decline typically occurs.
Safety data remained favorable. The most common adverse events were mild to moderate elevations in liver enzymes; no serious events such as anaphylaxis, thrombotic microangiopathy or malignancy were reported. The absence of severe safety signals strengthens the case for accelerated approval under the FDA’s priority‑review pathway, which Ultragenyx received in February 2025.
Ultragenyx resubmitted its Biologics License Application (BLA) for UX111 following a Complete Response Letter in July 2025. The company’s priority‑review status and the anticipated PDUFA date in the third quarter of 2026 position UX111 as a potential first‑in‑class therapy for MPS IIIA. The sustained efficacy data directly address the FDA’s concerns about durability and support the company’s argument for accelerated approval, which could open a market for a disease with no approved treatments.
The clinical milestone is a key driver for Ultragenyx’s rare‑disease pipeline, but the company continues to face financial headwinds. Q4 2025 earnings, scheduled for February 12 2026, are expected to show ongoing losses and negative cash flow, reflecting the high cost of clinical development and limited revenue streams. Despite these challenges, the positive data may improve investor confidence in the company’s long‑term strategy, while analysts have tempered enthusiasm with concerns about the firm’s cash runway and valuation multiples.
Ultragenyx’s CEO, Emil D. Kakkis, emphasized the urgency of the therapy, stating, “Families have no way to halt this devastating progression. We’re partnering with regulators to speed access.” Analysts have reiterated buy or overweight ratings, maintaining price targets in the $44–$60 range, but have also lowered targets in light of the company’s financial profile. The market reaction reflects a balance between optimism over the clinical breakthrough and caution regarding the firm’s financial sustainability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.